However, recent studies have suggested that galectin-3 can help to predict prognosis of heart failure and adverse events in various clinical settings such as ST elevation myocardial infraction [28], congenital heart disease patients with a Fontan circulation [29] and survivors of out-of-hospital cardiac arrest [30]. Here, LGALS3 is linked to heart failure.